PCSK9 inhibition potentiates cancer immune checkpoint therapy

Despite its great success, cancer immune therapy is still of limited efficacy in the majority of cancer patients(1,2). Many efforts are underway to identify novel approaches to enhance immune checkpoint therapy(3–5). Here we show that inhibition of PCSK9, a key protein in regulating cholesterol meta...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xinjian, Bao, Xuhui, Hu, Mengjie, Chang, Hanman, Jiao, Meng, Cheng, Jin, Xie, Liyi, Huang, Qian, Li, Fang, Li, Chuan-Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7770056/
https://www.ncbi.nlm.nih.gov/pubmed/33177715
http://dx.doi.org/10.1038/s41586-020-2911-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7770056/
https://www.ncbi.nlm.nih.gov/pubmed/33177715
http://dx.doi.org/10.1038/s41586-020-2911-7

Ejemplares similares